Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients

By sjmartinez • May 7, 2024

Bardia A, Sun S, Thimmiah N, Coates JT, Wu B, Abelman RO, Spring L, Moy B, Ryan P, Melkonyan MN, Partridge A, Juric D, Peppercorn J, Parsons H, Wander SA, Attaya V, Lormil B, Shellock M, Nagayama A, Bossuyt V, Isakoff SJ, Tolaney SM, Ellisen LW. Antibody Drug Conjugate Sacituzumab Govitecan Enables A Sequential TOP1/PARP Inhibitor Cancer Therapy Strategy in Breast Cancer Patients. Clin Cancer Res. 2024 May 6. doi: 10.1158/1078-0432.CCR-24-0428. Epub ahead of print. PMID: 38709212.

Tags: Hematology/Oncology, Publications

Impact of postoperative FDG-PET/CT on adjuvant head and neck cancer treatment

Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian[...]

Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management

Lisberg A, Huppert LA, Halmos B, Ledezma B, Soto-Romano V, Traina TA. Datopotamab Deruxtecan-Associated Select Adverse Events: Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring,[...]

Imaging Interoperability: #DitchtheDisk is a Health Equity Imperative for Lung Cancer Screening & Beyond

Tupper HI, Mendelson DS, Doo FX, Carlos RC, Bialecki B, Prosper AE, Moghanaki D, Servais EL, Flores EJ, Cummings AL. Imaging Interoperability: #DitchtheDisk is a[...]